British American Tobacco Share Discussion Threads

[cryptotrade] 31/1/2019 21:16

Bat have invested in vape. They knew this 8 years ago. The question is have they capitalized on this.

[philanderer] 31/1/2019 20:41

The Wall Street Journal @WSJ

9 minutes ago

Marlboro maker Altria said it sees U.S. cigarette sales falling even faster than it had expected, validating the company's recent $12.8 billion investment in vaping startup Juul

[cryptotrade] 31/1/2019 19:00

Give over. £45

[cryptotrade] 31/1/2019 18:58

8% yield ?

[barbar7619] 31/1/2019 14:11

2395 does look good now!!!

[andrewbaker] 31/1/2019 13:57

When the US opens, we could even get back over £27! :) 'Smoking' is the best way to describe what BATS will do this year, IMHO.

[philanderer] 31/1/2019 13:49

Nice pickup from midday :-)

[micha14] 31/1/2019 13:34

Yep, some serious buying happening in the UK today, can yesterdays comments from Piper Jeffrey swing the pendulum the other way? I believe its possible, especially when BAT posts a 9.3bln£ free cash flow in March. 9.3bln£, the Nayers will wake up and smoke a piece of New port, New it ll be for them when the patient holders would ve caught the Lucky Strike.

[andrewbaker] 31/1/2019 11:35

Whatever the arguments about tobacco businesses, BATS is here for the long term and will make money. At an 8% covered yield, paid quarterly, anyone with cash or income needs should consider this for a chunk of such funds. As I boringly say each time I blog, I already am so loaded up on this that anymore would be excessive: yet I still buy a few more now and then. I can't resist it: I'm hooked on their tobacco and I don't smoke! lol. 😂

[minerve] 31/1/2019 10:52

"Research suggests that the health risks of “vaping” are much lower than for traditional cigarettes – meaning, in essence, that smokers can feed their addiction more safely"

Long term risks are not known. Maybe, maybe not.

[wbecki] 31/1/2019 09:03

"Big Tobacco and Generation Vape"
E-cigarettes don’t just appeal to hardened smokers; they draw teenagers in as well

Research suggests that the health risks of “vaping” are much lower than for traditional cigarettes – meaning, in essence, that smokers can feed their addiction more safely.

Tobacco executives such as Calantzopoulos are pleading with regulators and investors to back their new “smokeless” pitch as part of a drive for better global health. “We know that smokeless products are much better,” he explained in Davos. “We need to take a scientific approach, to get away from all this emotion [about tobacco]. We all need to look at the facts.”

[dmore2] 31/1/2019 06:42

cannabis and vaping gonna be big part of bats future

[micha14] 30/1/2019 23:54

We wont see 23.95£ again.

[micha14] 30/1/2019 23:48

Its worth repeating-

Piper Jaffray's analysts DO NOT expect any operational impact "for years and years", as the rule-making process itself is lengthy and likely to be followed by "5-10 or more" years of legal challenges.
5+ YEARS OF LEGAL CHALLENGES AND NO OPERATION IMPACT.

Even me think thats a bit generous to BAT, but you get the point.

This is a 55-60£ stock in 18-24-36 months, and thats being conservative and underambitious

[gutterhead] 30/1/2019 22:28

Barbar
Quite agree with you

[barbar7619] 30/1/2019 22:01

#eeza....... very easy to say. Look at my post recently and see you in 2 years. Bought in at 2395 and I will see 4000 a share before I sell. Onwards and upwards. You won't see 2395 again chaps

[eeza] 30/1/2019 21:09

'They marched it up the hill, then they marched it down again'

Rinse & repeat.

[wbecki] 30/1/2019 20:44

But British American is now so undervalued that it's likely to deliver better total returns, making it the superior investment today (though both stocks are worth buying).

[minerve] 30/1/2019 18:28

Still got in at a good price Dean. I woudn't reflect on that at all. It is easier said than done. ;)

[deanforester] 30/1/2019 18:11

Added to my holding today. Should have done it sooner.

[wbecki] 30/1/2019 16:57

Cheers for the Piper comment Michal4.

[cheekyfella] 30/1/2019 12:58

nice bit of bin-dipping

[minerve] 30/1/2019 11:59

Well ATM, I pretty much bought my largest tranche at the exact bottom. Pure luck, of course.

[micha14] 30/1/2019 11:54

BAT VALUATION 'ATTRACTIVE' AND DIVIDEND LOOKS SAFE TO PIPER JAFFRAY
(Sharecast News) - Analysts at Piper Jaffray upgraded British American Tobacco from 'neutral' to 'overweight' on Tuesday, noting the industry giant's valuation appeared "attractive" at current levels.
While trimming its estimates on currency and more conservative US assumptions due to risks associated to with the FDA's ban on menthol cigarettes, Piper Jaffray maintained its £30 target on the firm, noting that much of the menthol related risks appeared priced in.

"While BAT has greater menthol exposure than its peers, risk from a potential ban already appears priced in."

Piper Jaffray's analysts do not expect any operational impact "for years and years", as the rule-making process itself is lengthy and likely to be followed by "5-10 or more" years of legal challenges.

While many investors have quailed at potential risks to dividend growth - the analysts do not see it, adding that BAT's cash flows appeared to be at no risk in any way that would impact its dividend.

"We have had questions from investors on risk to the dividend, reflecting concerns we do not share."

Piper Jaffray also noted that, while BAT's glo patent litigation in Japan was "still a risk", it conceded that it was perhaps less of one than it had initially believed.

[micha14] 30/1/2019 11:54

BAT VALUATION 'ATTRACTIVE' AND DIVIDEND LOOKS SAFE TO PIPER JAFFRAY
(Sharecast News) - Analysts at Piper Jaffray upgraded British American Tobacco from 'neutral' to 'overweight' on Tuesday, noting the industry giant's valuation appeared "attractive" at current levels.
While trimming its estimates on currency and more conservative US assumptions due to risks associated to with the FDA's ban on menthol cigarettes, Piper Jaffray maintained its £30 target on the firm, noting that much of the menthol related risks appeared priced in.

"While BAT has greater menthol exposure than its peers, risk from a potential ban already appears priced in."

Piper Jaffray's analysts do not expect any operational impact "for years and years", as the rule-making process itself is lengthy and likely to be followed by "5-10 or more" years of legal challenges.

While many investors have quailed at potential risks to dividend growth - the analysts do not see it, adding that BAT's cash flows appeared to be at no risk in any way that would impact its dividend.

"We have had questions from investors on risk to the dividend, reflecting concerns we do not share."

Piper Jaffray also noted that, while BAT's glo patent litigation in Japan was "still a risk", it conceded that it was perhaps less of one than it had initially believed.